LDC1267 ole 4R)-1-[(2S)-2-(2-{3-[4-(3-{4-[(5-bromo-4-{[3-(1-cyclobutyl-N-methylformamido)propyl]amino}pyrimidin-2-yl)amino]phenoxy}propoxy)butoxy]propoxy}acetamido)-3

4R)-1-[(2S)-2-(2-{3-[4-(3-{4-[(5-bromo-4-{[3-(1-cyclobutyl-N-methylformamido)propyl]amino}pyrimidin-2-yl)amino]phenoxy}propoxy)butoxy]propoxy}acetamido)-3

also degrades the polybromo-associated BAF (PBAF) complex member PBRM1

PubMed PMID: 17785584

Control of cambendazole-resistant small strongyles (Population S) with oxibendazole in a pony band: an 8 year field test (1984-1992)

ZSTK474 blocks VEGF-induced cell migration and the tube formation in human umbilical vein endothelial cells (HUVECs)

LDC1267 ole 4R)-1-[(2S)-2-(2-{3-[4-(3-{4-[(5-bromo-4-{[3-(1-cyclobutyl-N-methylformamido)propyl]amino}pyrimidin-2-yl)amino]phenoxy}propoxy)butoxy]propoxy}acetamido)-3LDC1267 is a potent and selective TAM kinase inhibitor. LDC1267 displays lower activity against Met, Aurora B, Lck, Src, and CDK8. LDC1267 markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl b. Treatment of wild type NK cells with a newly developed small molecule TAM kinase inhibitor